Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim-Mobilized PBSC for Allogeneic Transplantation
NCT00785525Phase 3Recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Feb 1997
- Primary completion
- Jan 2030
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgrastim in leukemia, hematologic diseases and Congenital disorders, sponsored by Center for International Blood and Marrow Transplant Research. Primary endpoint: Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from NMDP donors. Started Feb 1997; status: recruiting.
02
Drugs
filgrastim
03
Conditions
leukemiahematologic diseasesCongenital disorders
Beyond the preview
Go deeper on NCT00785525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785525.